MétaCan
Menu
Back to cohort
Record W4387569270 · doi:10.21203/rs.3.rs-3383063/v1

In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile

2023· preprint· en· W4387569270 on OpenAlexafffund
Jong‐Won Kim, Ho Jae Han, Jaeyoon Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Dennis Dong Huan Kim

Bibliographic record

VenueResearch Square · 2023
Typepreprint
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health Network
FundersKorea Drug Development FundNational Research Foundation of KoreaNational Research FoundationMinistry of Science and ICT, South KoreaPrincess Margaret Cancer Foundation
KeywordsTyrosine kinaseIn vitroProto-oncogene tyrosine-protein kinase SrcKinaseProtein kinase domainChemistryPharmacologyMutationReceptor tyrosine kinaseCancer researchBiologyBiochemistrySignal transductionMutantGene

Abstract

fetched live from OpenAlex

Abstract Background Asciminib (ASC), inhibiting ABL1 myristoyl pocket, has a different action mechanism from ATP-binding pocket inhibitors (ABPIs). We hypothesized that tyrosine kinase inhibitor (TKI) resistance mediated by ABL1 kinase domain mutation (KDM) can be reversed by combination of ASC with ABPI. Methods The efficacy and synergy of combination of ASC with ABPIs was evaluated in 11 different BaF3 cell lines including wild type (WT), G250E, E255K, T315A, M351T, F317L, F317V, H396P, Y253F, M244V, T315I mutant ones and WT K562 cell line. Results Combining fixed dose ASC with the reduced doses of ABPI was feasible to inhibit CML/WT cell lines completely. According to sensitivity to the combination of ABPIs with fixed dose ASC, ABL1 KDM cell lines are stratified into high (G250E, E255K, T315A), intermediate (M351T, F317L) or low sensitivity (F317V, H396P, Y253F, M244V and T315I). Reduced dose ABPI combined with fixed dose ASC showed similar efficacy to full dose ABPIs alone in high and intermediate sensitive cells. Ponatinib dose can be reduced to 25% when combined with ASC, but exerting similar efficacy to full dose ponatinib. Conclusion The present study provides in vitro evidence of the synergistic efficacy of the combination of ASC with reduced dose of ABPI including dasatinib/ponatinib.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.077
GPT teacher head0.394
Teacher spread0.316 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueResearch SquareSame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207